2020/01/08 by Hillary A Vanderven, Hillary A. Vanderven, Stephen J. Kent +1 · 1 voice · 2 citations
Medicine · #Influenza Virus Research Studies #Monoclonal and Polyclonal Antibodies Research #Respiratory viral infections research
paper · pdf · doi:10.1111/imcb.12312
openalex publication_date 2020/01/08 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/29
In recent years, there has been a renewed interest in utilizing antibody fragment crystallizable (Fc) functions to prevent and control viral infections. The protective and therapeutic potential of Fc-mediated antibody functions have been assessed for some clinically important human viruses, including HIV, hemorrhagic fever viruses and influenza virus. There is mounting evidence that influenza-specific antibodies with Fc-mediated functions, such as antibody-dependent cellular cytotoxicity and antibody-dependent phagocytosis, can aid in the clearance of influenza virus infection. Recent influenza challenge studies and intravenous immunoglobulin G therapy studies in humans suggest a protective role for Fc effector functions in vivo. Broadly reactive influenza antibodies with Fc-mediated functions are prevalent in the human population and could inform the development of a universally protective influenza vaccine or therapy. In this review, we explore the utility of antibodies with Fc-mediated effector functions against viral infections with a focus on influenza virus.